
Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell therapies for diabetes and lupus.

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell therapies for diabetes and lupus.